[Salazosulfapyridine in rheumatoid arthritis. A study of 49 patients].
[Salazosulfapyridine in rheumatoid arthritis. A study of 49 patients].
复制标题
[柳氮磺胺吡啶治疗类风湿性关节炎。
DOI：
--
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
C. Menkès
中科院分区：
文献类型：
--
作者：
P. Hilliquin;A. Muñoz;C. Menkès
本文报告了49例用柳氮磺胺吡啶（SASP）（柳氮磺胺吡啶）治疗类风湿关节炎（RA）的开放回顾性研究结果。患者中，7名男性和42名女性，平均年龄为53岁，他们的平均病程为13.3年。其中60%的人曾接受过3种以上的疾病改善药物。平均治疗时间为15.3个月。34例患者（69%）的初始反应良好。12例（24.5%）治疗无效并停止治疗，6例为原发性无效，另6例为快速治疗。20名患者（41%）至少出现了一种副作用。11例患者（20.4%）因不良反应而停用SASP; 11次中有9次发生在治疗的前2个月。消化系统不耐受是最常见的，但导致不到一半的患者停药。在所有病例中，皮肤粘膜、感觉神经、血液学和肝脏副作用在SASP停药后一个月内消退。治疗维持水平在1年时为67%，18个月时为60%，2年时为52%，3年时为45%。在开甲氨蝶呤处方之前，SASP在治疗相对轻微演变形式的RA中发挥作用。延迟不耐受反应的可能性，特别是血液学和肝脏反应，证明对这些患者进行长期生物学监测是合理的。
The results of an open retrospective study of 49 patients treated with salazosulfapyridine (SASP) (sulphasalazine) for rheumatoid arthritis (RA) are reported. The patients, 7 men and 42 women, had a mean age of 53 years, and their mean duration of evolution of RA was 13.3 years. Sixty percent of them had undergone more than 3 previous disease-modifying drugs. The mean length of SASP treatment was 15.3 months. The initial response was favorable in 34 patients (69%). Treatment was ineffective and stopped in 12 cases (24.5%); the inefficacy was primary in 6 and tachyphylactic in the other 6. Twenty patients (41%) experienced at least one side effect. SASP was stopped in 11 patients (20.4%) due to undesirable side effects; 9 of the 11 times were during the first 2 months of treatment. Digestive system intolerance was the most common but led to drug withdrawal in less than half the patients. In all cases, mucocutaneous, neurosensory, hematological and hepatic side effects regressed during the month following SASP withdrawal. The therapeutic maintenance level was 67% at 1 year, 60% at 18 months, 52% at 2 years and 45% at 3 years. SASP has a role in the treatment of relatively slightly evolved forms of RA, before prescribing methotrexate. The possibility of delayed intolerance reactions, notably hematological and hepatic, justify prolonged biological monitoring of these patients.